½ÃÀ庸°í¼­
»óǰÄÚµå
1423637

Á÷Á¢ ±Þ¿© »ý±Õ(DFM) ½ÃÀå ¿¹Ãø(-2030³â) : À¯Çü, ÇüÅÂ, À¯·¡, Á¦Á¦, °¡Ãà, ÀÎÁõ, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ªº° ¼¼°è ºÐ¼®

Direct-Fed Microbials Market Forecasts to 2030 - Global Analysis By Type, Form, Source, Formulation, Livestock, Certification, Application, End User and By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Stratistics Market Research Consulting | ÆäÀÌÁö Á¤º¸: ¿µ¹® 200+ Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Stratistics MRC¿¡ µû¸£¸é ¼¼°èÀÇ Á÷Á¢ ±Þ¿© »ý±Õ(DFM) ½ÃÀåÀº 2023³â¿¡ 16¾ï 2,000¸¸ ´Þ·¯¸¦ Â÷ÁöÇÏ°í ¿¹Ãø ±â°£ Áß CAGR 8.8%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 29¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

µ¿¹°¿ë ÇÁ·Î¹ÙÀÌ¿Àƽ½º·Îµµ ¾Ë·ÁÁø Á÷Á¢ ±Þ¿© »ý±Õ(DFM)Àº ÀûÀýÇÑ ¾çÀ» Åõ¿©ÇÏ¸é ¼÷ÁÖ µ¿¹°¿¡°Ô °Ç°­»óÀÇ ÀÌÁ¡À» Á¦°øÇÏ´Â »ì¾ÆÀÖ´Â ¹Ì»ý¹°(¹ÚÅ׸®¾Æ ¶Ç´Â È¿¸ð)À» ¸»ÇÕ´Ï´Ù. °¡Ãà°ú °¡±Ý·ù »ý»ê¿¡ ³Î¸® »ç¿ëµÇ´Â DFMÀº ±ÕÇü ÀâÈù Àå³» ¼¼±ÕÃÑÀ» ÃËÁøÇÏ°í ¼ÒÈ­, ¿µ¾ç Èí¼ö ¹× ¸é¿ª°è ±â´ÉÀ» µ½½À´Ï´Ù. ÀÌ·¯ÇÑ ¹Ì»ý¹°Àº À¯ÇØÇÑ º´¿ø¼º ¹ÚÅ׸®¾Æ¿¡ ´ëÇ×Çϰí ÀåÀÇ Àü¹ÝÀûÀÎ °Ç°­À» °³¼±Çϸç, DFMÀÇ º¸ÃæÀº °¡ÃàÀÇ »ç·á È¿À², ¼ºÀå·ü ¹× Áúº´ ÀúÇ×¼ºÀ» Çâ»ó½ÃŰ´Â °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

National Center for Biotechnology Information(NCBI)¿¡ µû¸£¸é Ç×»ýÁ¦ ¾ø´Â °¡±Ý·ù¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í Àß Á¶»çµÈ ÀåÁ¡À¸·Î ÀÎÇØ °¡±Ý·ù¿¡ ´ëÇÑ ÇÁ·Î¹ÙÀÌ¿Àƽ½º »ç¿ëÀº CAGR 7.7%·Î Á¡ÁøÀûÀ¸·Î È®´ëµÇ¾î 2025³â¿¡´Â 1¾ï 2,500¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Ãà»ê¹°¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡

¼¼°è Àα¸ Áõ°¡¿Í ÇÔ²² µ¿¹°¼º Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϸ鼭 Ãà»ê¹° »ý»êÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. µ¿¹°ÀÇ ¿µ¾ç°ú °Ç°­À» °­È­ÇÏ´Â °ÍÀ¸·Î ¾Ë·ÁÁø Á÷Á¢ »ç·á ¹Ì»ý¹°ÀÌ ÀÌ·¯ÇÑ ¼ö¿ä¿¡ ºÎÀÀÇÏ¿© Àα⸦ ²ø°í ÀÖ½À´Ï´Ù. ³«³ó°¡´Â »ç·á È¿À²À» ³ôÀ̰í, ¼ºÀåÀ» °¡¼ÓÇϰí, µ¿¹°ÀÇ ½ºÆ®·¹½º ¿äÀο¡ ´ëóÇϱâ À§ÇØ DFM º¸ÃæÁ¦¸¦ äÅÃÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â °¡Ãà °ü¸® ºÐ¾ßÀÇ DFM ½ÃÀå È®´ë¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

Á¦ÇÑµÈ À¯Åë±âÇѰú ¾ÈÁ¤¼º

Á÷Á¢ ±Þ¿© »ý±Õ(DFM)Àº ¿Âµµ ¹Î°¨¼º, ½Àµµ, ȯ°æ Á¶°ÇÀÇ ¿µÇâÀ» ¹Þ±â ½±±â ¶§¹®¿¡ º¸Á¸ ±â°£°ú ¾ÈÁ¤¼º¿¡ ÇѰ谡 ÀÖ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ÀÌ·¯ÇÑ ÇѰè´Â Á¦Ç°³» ¹Ì»ý¹°ÀÇ »ýÁ¸¼ºÀ» Àå±â°£ À¯ÁöÇÏ´Â µ¥ ¾î·Á¿òÀ» °Þ°í ÀÖ½À´Ï´Ù. À¯Åë±âÇÑÀÌ Âª¾ÆÁö¸é Á¦Ç°À» ÀÚÁÖ ±³Ã¼ÇØ¾ß Çϱ⠶§¹®¿¡ »ý»êºñ¿ëÀÌ »ó½ÂÇϰí À¯Åë ¼±ÅñÇÀÌ Á¦ÇÑµÇ¾î ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀÌ µË´Ï´Ù.

µ¿¹° ¿µ¾ç¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡

±ÕÇü ÀâÈù ½Ä´ÜÀÇ Á߿伺¿¡ ´ëÇÑ °¡Ãà ¹× ¹Ý·Áµ¿¹° º¸È£ÀÚµéÀÇ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ DFM Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹Ì»ý¹°Àº Àå °Ç°­À» Áö¿øÇÏ°í ¿µ¾ç Èí¼ö¸¦ °³¼±ÇÏ´Â ´É·ÂÀ¸·Î ÁÖ¸ñÀ» ¹Þ°í ÀÖ½À´Ï´Ù. µ¿¹°ÀÇ ¿µ¾ç°ú °ü¸®¿¡ ´ëÇÑ Àû±ØÀûÀÎ Á¢±Ù ¹æ½ÄÀ» ¼±È£ÇÏ´Â °æÇâÀº µ¿¹°»ç·á¿¡¼­ DFMÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖ´Â °ÍÀ¸·Îµµ ¾Ë ¼ö ÀÖÀ¸¸ç, ÀÌ´Â µ¿¹°ÀÇ ÀüÀÎÀû º¹Áö¸¦ ÇâÇÑ ½ÃÀå ¿ªÇÐÀÇ ±¤¹üÀ§ÇÑ º¯È­¸¦ Áö¿øÇÕ´Ï´Ù.

Ç×»ýÁ¦¿ÍÀÇ Ãæµ¹

Á÷Á¢ ¸ÔÀÌ »ý±Õ(DFM)Àº °¡Ãà°ú °¡±Ý·ù »çÀ°¿¡ Ç×»ýÁ¦¸¦ ÇÔ²² »ç¿ëÇÏ´Â °æ¿ì°¡ ¸¹±â ¶§¹®¿¡ Ç×»ýÁ¦·Î ÀÎÇÑ Å« À§Çè¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. Ç×»ýÁ¦´Â ÀüÅëÀûÀÎ ¼ºÀå ÃËÁøÁ¦À̱⠶§¹®¿¡ DFM Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä¸¦ °¨¼Ò½ÃÄÑ ½ÃÀå Á¡À¯À²À» ¶³¾î¶ß¸± ¼ö ÀÖ½À´Ï´Ù. Ç×»ýÁ¦ ³»¼º¿¡ ´ëÇÑ ¿ì·Á´Â ±ÔÁ¦ Á¶Ä¡°¡ Ç×»ýÁ¦ ´ëüǰÀ» ¿ì¼±½Ã ÇÒ ¼ö ÀÖÀ¸¹Ç·ÎÀÌ °æÀïÀ» ´õ¿í ½ÉÈ­½Ãų °ÍÀÔ´Ï´Ù. µû¶ó¼­ ÀÌ·¯ÇÑ Ãø¸éÀÌ ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

COVID-19ÀÇ ¿µÇâ

COVID-19 ÆÒµ¥¹ÍÀº °ø±Þ¸ÁÀ» È¥¶õ¿¡ ºü¶ß¸®°í »ý»ê¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ¼ÒºñÀÚÀÇ ¿ì¼±¼øÀ§¸¦ ¹Ù²Ù¸é¼­ Á÷Á¢ »ç·á¿ë »ý±ÕÁ¦(DFM) ½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ºÀ¼â Á¶Ä¡¿Í °æÁ¦ ºÒÈ®½Ç¼ºÀ¸·Î ÀÎÇØ ³ó¾÷ ¹× Ãà»ê ºÎ¹®ÀÇ DFM Á¦Ç° À¯Åë ¹× µµÀÔ¿¡ ¾î·Á¿òÀ» °Þ¾ú½À´Ï´Ù. ±×·¯³ª °¡ÃàÀÇ °Ç°­°ú ¸é¿ª·ÂÀÇ Á߿伺¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ³ó°¡¿Í »ý»êÀÚ°¡ Àü¿°º´ÀÇ ¿©ÆÄ ¼Ó¿¡¼­ °¡ÃàÀÇ °Ç°­À» Çâ»ó½Ãų ¼ö ÀÖ´Â ÇØ°áÃ¥À» ¸ð»öÇϸ鼭 DFM¿¡ ´ëÇÑ ÇâÈÄ ¼ö¿ä¸¦ ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù.

¿¹Ãø ±â°£ Áß °¡±Ý·ù ºÎ¹®ÀÌ °¡Àå Ŭ °ÍÀ¸·Î ¿¹»ó

°¡±Ý·ù ºÎ¹®Àº ¼ÒÈ­, ¿µ¾ç Èí¼ö ¹× ¸é¿ª ±â´É °³¼±À¸·Î ÀÎÇØ À¯¸®ÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Á÷Á¢ ±Þ¿© »ý±ÕÁ¦(DFM)´Â Àå °Ç°­°ú Àü¹ÝÀûÀÎ ¼º´ÉÀ» Çâ»ó½ÃÄÑ °¡±Ý·ù »çÀ°¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ À¯ÀÍÇÑ ¹Ì»ý¹°Àº Á¾Á¾ ¹ÚÅ׸®¾Æ¿Í È¿¸ð¿Í °°Àº ÇÁ·Î¹ÙÀÌ¿Àƽ½º·Î ±¸¼ºµÇ¾î ´ßÀÇ Àå³» ¼¼±ÕÃÑ ±ÕÇüÀ» ÃËÁøÇÕ´Ï´Ù. ¶ÇÇÑ Ç×»ýÁ¦¸¦ »ç¿ëÇÏÁö ¾Ê´Â Áö¼Ó°¡´ÉÇÑ Ç×»ýÁ¦ »ç¿ë°ú ÀÏÄ¡ÇÏ¿© ´õ °Ç°­ÇÑ ¾ç°èÀå°ú ´õ ³ôÀº »ý»ê¼ºÀ» º¸ÀåÇÕ´Ï´Ù.

½ºÆ®·¹½º °ü¸® ºÐ¾ß´Â ¿¹Ãø ±â°£ Áß °¡Àå ³ôÀº CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»ó

½ºÆ®·¹½º °ü¸® ºÐ¾ß´Â ¿¹Ãø ±â°£ Áß °¡Àå ³ôÀº CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Á÷Á¢ »ç·áÈ­ ¹Ì»ý¹°(DFMs)Àº ½ºÆ®·¹½º °ü¸®ÀÇ ÀáÀç·ÂÀ¸·Î ¾Ë·ÁÁø À¯ÀÍÇÑ ¹ÚÅ׸®¾Æ¿Í È¿¸ð º¸ÃæÁ¦ÀÔ´Ï´Ù. °Ç°­ÇÑ Àå³» ¼¼±ÕÃÑÀ» ÃËÁøÇÔÀ¸·Î½á DFMÀº ¿µ¾ç Èí¼ö¿Í ¸é¿ª ±â´É Çâ»ó¿¡ ±â¿©ÇÏ°í ½ºÆ®·¹½º¸¦ ¿ÏÈ­ÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ÀÌ ¹Ì»ý¹°Àº ¶ÇÇÑ ±ÕÇü ÀâÈù ¼ÒÈ­ ½Ã½ºÅÛÀ» À¯ÁöÇÏ°í ½Å°æ Àü´Þ ¹°ÁúÀÇ »ý»ê¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡¸ç ÇÇÁú ¼öÁØÀ» ³·Ãß´Â µ¥ µµ¿òÀ» ÁÝ´Ï´Ù.

°¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÏ´Â Áö¿ª :

¾Æ½Ã¾ÆÅÂÆò¾çÀº Ãà»ê¹°¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í µ¿¹° °Ç°­¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¿¹Ãø ±â°£ Áß °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Àα¸ Áõ°¡, °¡Ã³ºÐ ¼Òµæ Áõ°¡, °íǰÁú Ãà»ê¹°·ÎÀÇ Àüȯ µîÀÇ ¿äÀÎÀÌ ½ÃÀå È®´ë¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Áö¼Ó°¡´ÉÇÑ ³ó¾÷À» Àå·ÁÇϱâ À§ÇÑ Á¤ºÎÀÇ ±¸»óµµ ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

CAGRÀÌ °¡Àå ³ôÀº Áö¿ª :

À¯·´Àº °¡Ãà ¹× °¡±Ý·ù Àå °Ç°­ÀÇ Á߿伺¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¿¹Ãø ±â°£ Áß °¡Àå ³ôÀº CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÚ¿¬ÀûÀ̰í Áö¼Ó°¡´ÉÇÑ µ¿¹° ¿µ¾ç ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í Ãà»ê¾÷¿¡¼­ Ç×»ýÁ¦ »ç¿ë¿¡ ´ëÇÑ ¾ö°ÝÇÑ ±ÔÁ¦¿Í ÇÔ²² ½ÃÀå È®´ë¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ À¯·´ÀÇ DFM ½ÃÀåÀº ´õ °Ç°­Çϰí ģȯ°æÀûÀÎ °¡ÃàÀ¸·ÎÀÇ ÀüȯÀ» ¹Ý¿µÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ÀÌ Áö¿ªÀÇ Áö¼Ó°¡´ÉÇÑ ³ó¾÷¿¡ ´ëÇÑ ¾à¼ÓÀ» °­Á¶Çϰí ÀÖ½À´Ï´Ù.

¹«·á Ä¿½ºÅ͸¶ÀÌ¡ ¼­ºñ½º

ÀÌ º¸°í¼­¸¦ ±¸µ¶ÇÏ´Â °í°´Àº ´ÙÀ½°ú °°Àº ¹«·á ¸ÂÃãÈ­ ¿É¼Ç Áß Çϳª¸¦ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. :

  • ±â¾÷ °³¿ä
    • Ãß°¡ ½ÃÀå ±â¾÷ÀÇ Á¾ÇÕÀûÀÎ ÇÁ·ÎÆÄÀϸµ(ÃÖ´ë 3»ç)
    • ÁÖ¿ä ±â¾÷ÀÇ SWOT ºÐ¼®(ÃÖ´ë 3»ç)
  • Áö¿ª ¼¼ºÐÈ­
    • °í°´ÀÇ °ü½É¿¡ µû¸¥ ÁÖ¿ä ±¹°¡º° ½ÃÀå ÃßÁ¤Ä¡, ¿¹Ãø, CAGR(ÁÖ: Ÿ´ç¼º È®Àο¡ µû¶ó ´Ù¸§)
  • °æÀï»ç º¥Ä¡¸¶Å·
    • Á¦Ç° Æ÷Æ®Æú¸®¿À, Áö¿ªÀû ÀÔÁö, Àü·«Àû Á¦ÈÞ¸¦ ±â¹ÝÀ¸·Î ÇÑ ÁÖ¿ä ±â¾÷ º¥Ä¡¸¶Å·

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼­¹®

  • °³¿ä
  • ÀÌÇØ°ü°èÀÚ
  • Á¶»ç ¹üÀ§
  • Á¶»ç ¹æ¹ý
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • µ¥ÀÌÅÍ ºÐ¼®
    • µ¥ÀÌÅÍ °ËÁõ
    • Á¶»ç ¾îÇÁ·ÎÄ¡
  • Á¶»ç ¼Ò½º
    • 1Â÷ Á¶»ç ¼Ò½º
    • 2Â÷ Á¶»ç ¼Ò½º
    • ÀüÁ¦Á¶°Ç

Á¦3Àå ½ÃÀå µ¿Ç⠺м®

  • ÃËÁø¿äÀÎ
  • ¾ïÁ¦¿äÀÎ
  • ±âȸ
  • À§Çù
  • ¾ÖÇø®ÄÉÀÌ¼Ç ºÐ¼®
  • ÃÖÁ¾»ç¿ëÀÚ ºÐ¼®
  • ½ÅÈï ½ÃÀå
  • ½ÅÁ¾ Äڷγª¹ÙÀÌ·¯½º °¨¿°Áõ(COVID-19)ÀÇ ¿µÇâ

Á¦4Àå Porter's Five Forces ºÐ¼®

  • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
  • ±¸¸ÅÀÚÀÇ ±³¼··Â
  • ´ëüǰÀÇ À§Çù
  • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
  • °æÀï ±â¾÷°£ °æÀï °ü°è

Á¦5Àå ¼¼°èÀÇ Á÷Á¢ ±Þ¿© »ý±Õ(DFM) ½ÃÀå : À¯Çüº°

  • À¯»ê±Õ(LAB)
  • °íÃʱÕ
  • ºñÇÇ´õ½º±Õ
  • ¿¬¼â±¸±Õ
  • À屸±Õ
  • Æäµð¿ÀÄÚÄí½º
  • »çÄ«·Î¹Ì¼¼½º ¼¼·¹ºñ½Ã¾Æ
  • ÇÁ·ÎÇǿ»ê±Õ
  • ±âŸ À¯Çü

Á¦6Àå ¼¼°èÀÇ Á÷Á¢ ±Þ¿© »ý±Õ(DFM) ½ÃÀå : Çüź°

  • ºÐ¸»
  • ¾×ü
  • ĸ½¶
  • ±âŸ ÇüÅÂ

Á¦7Àå ¼¼°èÀÇ Á÷Á¢ ±Þ¿© »ý±Õ(DFM) ½ÃÀå : À¯·¡º°

  • õ¿¬
  • ÇÕ¼º

Á¦8Àå ¼¼°èÀÇ Á÷Á¢ ±Þ¿© »ý±Õ(DFM) ½ÃÀå : Á¦Á¦º°

  • ĸ½¶È­ Á¦Á¦
  • ÄÚÆÃ Á¦Á¦
  • ºí·»µå Á¦Á¦
  • ¹ßÈ¿ Á¦Á¦
  • ¾ÈÁ¤È­ Á¦Á¦
  • ±âŸ Á¦Á¦

Á¦9Àå ¼¼°èÀÇ Á÷Á¢ ±Þ¿© »ý±Õ(DFM) ½ÃÀå : °¡Ãະ

  • ¹ÝÃßµ¿¹°
    • ¼Ò
    • ¾ç
    • ¿°¼Ò
  • °¡±Ý
    • ´ß
    • ¿À¸®
    • Ä¥¸éÁ¶
  • µÅÁö
  • ¼ö»ê¾ç½Ä
    • ¾î·ù
    • »õ¿ì
  • ¹Ý·Áµ¿¹°
    • °³
    • °í¾çÀÌ
  • ¸»
  • Åä³¢
  • ±âŸ °¡Ãà

Á¦10Àå ¼¼°èÀÇ Á÷Á¢ ±Þ¿© »ý±Õ(DFM) ½ÃÀå : ¿ëµµº°

  • ½ºÆ®·¹½º °ü¸®
  • Ç×»ýÁ¦ ´ëüǰ
  • üÁß Áõ°¡
  • ¸é¿ª ±â´É
  • º´¿ø¼º °¨¿°Áõ
  • ¼¶À¯ ¼ÒÈ­
  • ±âŸ ¿ëµµ

Á¦11Àå ¼¼°èÀÇ Á÷Á¢ ±Þ¿© »ý±Õ(DFM) ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • ³ó¹Î
  • ¹Ý·Áµ¿¹° ¼ÒÀ¯ÁÖ
  • ¾ß»ýµ¿¹° ÀçȰ ¼¾ÅÍ
  • µ¿¹°º´¿ø
  • ±âŸ ÃÖÁ¾»ç¿ëÀÚ

Á¦12Àå ¼¼°èÀÇ Á÷Á¢ ±Þ¿© »ý±Õ(DFM) ½ÃÀå : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • ´ºÁú·£µå
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ³²¹Ì
    • ¾Æ¸£ÇîÆ¼³ª
    • ºê¶óÁú
    • Ä¥·¹
    • ±âŸ ³²¹Ì
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • īŸ¸£
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦13Àå ÁÖ¿ä ¹ßÀü

  • °è¾à, ÆÄÆ®³Ê½Ê, Çù¾÷, ÇÕº´»ç¾÷
  • ÀμöÇÕº´
  • ½ÅÁ¦Ç°ÀÇ ¹ß¸Å
  • »ç¾÷ È®´ë
  • ±âŸ ÁÖ¿ä Àü·«

Á¦14Àå ±â¾÷ °³¿ä

  • Chr. Hansen Holding A/S
  • Lallemand Inc.
  • Koninklijke DSM N.V.
  • Novozymes A/S
  • Microba Life Sciences
  • Archer Daniels Midland Company(ADM)
  • Kemin Industries Inc.
  • DuPont de Nemours Inc.
  • Cargill Incorporated
  • Evonik Industries AG
  • Alltech Inc.
  • Calpis Limited
  • Phibro Animal Health
  • Biomin Holding GmbH
  • Bayer AG
  • Probi AB
  • Novus International
  • Sabinsa Corporation
  • Kerry Group
  • Unique Biotech Limited
KSA 24.02.20

According to Stratistics MRC, the Global Direct-Fed Microbials (DFM) Market is accounted for $1.62 billion in 2023 and is expected to reach $2.92 billion by 2030 growing at a CAGR of 8.8% during the forecast period. Direct-Fed Microbials (DFMs), also known as probiotics for animals, refer to live microorganisms (bacteria or yeast) that can confer health benefits to the host animal when administered in adequate amounts. Widely used in livestock and poultry production, DFM promote a balanced gut microbiota, aiding in digestion, nutrient absorption, and immune system function. These microorganisms can outcompete harmful pathogens, enhancing overall gut health. DFM supplementation is believed to improve feed efficiency, growth rates, and disease resistance in animals.

According to The National Center for Biotechnology Information (NCBI), because of the rising demand for antibiotic-free poultry and its well-researched benefits, the use of probiotics in poultry has progressively expanded at a compound annual growth rate of 7.7%, over time, which is expected to reach 125 million USD by 2025.

Market Dynamics:

Driver:

Growing demand for livestock products

With a rising global population, there is a heightened need for animal-derived goods, prompting greater livestock production. Direct-Fed Microbials, known for enhancing animal nutrition and health, are gaining popularity in response to this demand. Farmers are adopting DFM supplements to boost feed efficiency, stimulate growth, and address stressors in animals. This trend is fueling the expansion of the DFM market within the livestock management sector.

Restraint:

Limited shelf life & stability

Direct-fed microbials (DFMs) often have limited shelf life and stability due to factors like temperature sensitivity, moisture, and susceptibility to environmental conditions. This limitation poses challenges in maintaining the viability of microorganisms in the product over time. The reduced shelf life hampers market growth as it necessitates frequent product turnover, increasing production costs and limiting distribution options.

Opportunity:

Rising awareness of animal nutrition

The heightened awareness among livestock and pet owners regarding the significance of well-balanced diets is boosting the demand for DFM products. These microbials are gaining prominence for their ability to support gut health and improve nutrient absorption. The growing preference for proactive approaches to animal nutrition and care is evident in the rising adoption of DFM in animal feed, underscoring a broader shift in the market dynamics towards holistic animal well-being.

Threat:

Competition from antibiotics

The direct-fed microbials (DFM) faces a significant hazard from antibiotics as they are often used interchangeably in livestock and poultry farming. Antibiotics, being traditional growth promoters, may overshadow the demand for DFM products, leading to a decline in market share. Concerns over antibiotic resistance further intensify this competition, as regulatory measures may prioritize antibiotic alternatives. Therefore, this aspect hampers the market growth.

Covid-19 Impact

The covid-19 pandemic has influenced the direct-fed microbials (DFM) market by disrupting supply chains, impacting production, and altering consumer priorities. Lockdown measures and economic uncertainties have led to challenges in the distribution and adoption of DFM products in the agricultural and livestock sectors. However, increased awareness of the importance of animal health and immunity may drive future demand for DFM as farmers and producers seek solutions to enhance the well-being of livestock in the aftermath of the pandemic.

The poultry segment is expected to be the largest during the forecast period

The poultry segment is estimated to have a lucrative growth, due to improved digestion, nutrient absorption, and immune function. Direct-Fed Microbials (DFMs) play a crucial role in poultry farming by enhancing gut health and overall performance. These beneficial microorganisms, often comprising probiotics like bacteria and yeast, promote a balanced gut microbiota in chickens. Further, their use aligns with sustainable and antibiotic-free practices, ensuring healthier flocks and higher productivity in poultry production.

The stress management segment is expected to have the highest CAGR during the forecast period

The stress management segment is anticipated to witness the highest CAGR growth during the forecast period. Direct-Fed Microbials (DFMs) are beneficial bacteria and yeast supplements known for their potential in stress management. By promoting a healthy gut microbiota, DFMs contribute to improved nutrient absorption and immune function, crucial factors in mitigating stress. These microorganisms also aid in maintaining a balanced digestive system, positively influencing neurotransmitter production and reducing cortical levels.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to the increasing demand for livestock products and a growing awareness of animal health. Factors such as a burgeoning population, rising disposable income, and a shift towards quality animal products are driving market expansion. Additionally, government initiatives promoting sustainable agriculture practices contribute to the market's positive trajectory in the Asia Pacific region.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period, owing to increasing awareness of the importance of gut health in livestock and poultry. Rising demand for natural and sustainable animal nutrition solutions, coupled with stringent regulations on antibiotic use in animal farming, further fuels market expansion. Also, the European DFM market reflects a shift towards healthier and more eco-friendly livestock practices, emphasizing the region's commitment to sustainable agriculture.

Key players in the market

Some of the key players profiled in the Direct-Fed Microbials (DFM) Market include Chr. Hansen Holding A/S, Lallemand Inc., Koninklijke DSM N.V., Novozymes A/S, Microba Life Sciences, Archer Daniels Midland Company (ADM), Kemin Industries Inc., DuPont de Nemours Inc., Cargill Incorporated, Evonik Industries AG, Alltech Inc., Calpis Limited, Phibro Animal Health, Biomin Holding GmbH, Bayer AG, Probi AB, Novus International, Sabinsa Corporation, Kerry Group and Unique Biotech Limited.

Key Developments:

In June 2023, Kerry, a world leader in taste and nutrition, has launched its next generation Tastesense™ Advanced range of solutions, aimed at transforming the low and zero-sugar product market with an exceptional ability to deliver unparalleled sweetness and full-bodied mouthfeel, as well as sustainability benefits.

In April 2023, Microba Life Sciences entered into a new partnership with Aviwell, an agrifood data and life science technology company to combine Microba's world leading technology and experience in metagenomics and precision microbiome measurement with Aviwell's extensive capabilities in microbiome multi-omics analyses, bioinformatics, microbial isolation and culture, and in-vivo field applications.

In February 2019, Phibro, the New Jersey-based animal health company expanded its product line into direct-fed microbial sector. The goal of creating a direct-fed microbial was to improve the support provided to producers intent upon reducing their use of antimicrobials.

Types Covered:

  • Lactic Acid Bacteria (LAB)
  • Bacillus Subtilis
  • Bifidobacterium
  • Streptococcus
  • Enterococcus
  • Pediococcus
  • Saccharomyces Cerevisiae
  • Propionibacterium
  • Other Types

Forms Covered:

  • Powder
  • Liquid
  • Capsule
  • Other Forms

Sources Covered:

  • Natural
  • Synthetic

Formulations Covered:

  • Encapsulated Formulation
  • Coated Formulation
  • Blended Formulation
  • Fermented Formulation
  • Stabilized Formulation
  • Other Formulations

Livestocks Covered:

  • Ruminants
  • Poultry
  • Swine
  • Aquaculture
  • Pets
  • Horses
  • Rabbits
  • Other Livestocks

Applications Covered:

  • Stress Management
  • Antibiotic Alternatives
  • Weight Gain
  • Immune Function
  • Pathogenic Infections
  • Fiber Digestion
  • Other Applications

End Users Covered:

  • Farmers
  • Pet Owners
  • Wildlife Rehabilitation Centers
  • Veterinary Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Direct-Fed Microbials (DFM) Market, By Type

  • 5.1 Introduction
  • 5.2 Lactic Acid Bacteria (LAB)
  • 5.3 Bacillus Subtilis
  • 5.4 Bifidobacterium
  • 5.5 Streptococcus
  • 5.6 Enterococcus
  • 5.7 Pediococcus
  • 5.8 Saccharomyces Cerevisiae
  • 5.9 Propionibacterium
  • 5.10 Other Types

6 Global Direct-Fed Microbials (DFM) Market, By Form

  • 6.1 Introduction
  • 6.2 Powder
  • 6.3 Liquid
  • 6.4 Capsule
  • 6.5 Other Forms

7 Global Direct-Fed Microbials (DFM) Market, By Source

  • 7.1 Introduction
  • 7.2 Natural
  • 7.3 Synthetic

8 Global Direct-Fed Microbials (DFM) Market, By Formulation

  • 8.1 Introduction
  • 8.2 Encapsulated Formulation
  • 8.3 Coated Formulation
  • 8.4 Blended Formulation
  • 8.5 Fermented Formulation
  • 8.6 Stabilized Formulation
  • 8.7 Other Formulations

9 Global Direct-Fed Microbials (DFM) Market, By Livestock

  • 9.1 Introduction
  • 9.2 Ruminants
    • 9.2.1 Cattle
    • 9.2.2 Sheep
    • 9.2.3 Goats
  • 9.3 Poultry
    • 9.3.1 Chickens
    • 9.3.2 Ducks
    • 9.3.3 Turkeys
  • 9.4 Swine
  • 9.5 Aquaculture
    • 9.5.1 Fish
    • 9.5.2 Shrimp
  • 9.6 Pets
    • 9.6.1 Dogs
    • 9.6.2 Cats
  • 9.7 Horses
  • 9.8 Rabbits
  • 9.9 Other Livestocks

10 Global Direct-Fed Microbials (DFM) Market, By Application

  • 10.1 Introduction
  • 10.2 Stress Management
  • 10.3 Antibiotic Alternatives
  • 10.4 Weight Gain
  • 10.5 Immune Function
  • 10.6 Pathogenic Infections
  • 10.7 Fiber Digestion
  • 10.8 Other Applications

11 Global Direct-Fed Microbials (DFM) Market, By End User

  • 11.1 Introduction
  • 11.2 Farmers
  • 11.3 Pet Owners
  • 11.4 Wildlife Rehabilitation Centers
  • 11.5 Veterinary Clinics
  • 11.6 Other End Users

12 Global Direct-Fed Microbials (DFM) Market, By Geography

  • 12.1 Introduction
  • 12.2 North America
    • 12.2.1 US
    • 12.2.2 Canada
    • 12.2.3 Mexico
  • 12.3 Europe
    • 12.3.1 Germany
    • 12.3.2 UK
    • 12.3.3 Italy
    • 12.3.4 France
    • 12.3.5 Spain
    • 12.3.6 Rest of Europe
  • 12.4 Asia Pacific
    • 12.4.1 Japan
    • 12.4.2 China
    • 12.4.3 India
    • 12.4.4 Australia
    • 12.4.5 New Zealand
    • 12.4.6 South Korea
    • 12.4.7 Rest of Asia Pacific
  • 12.5 South America
    • 12.5.1 Argentina
    • 12.5.2 Brazil
    • 12.5.3 Chile
    • 12.5.4 Rest of South America
  • 12.6 Middle East & Africa
    • 12.6.1 Saudi Arabia
    • 12.6.2 UAE
    • 12.6.3 Qatar
    • 12.6.4 South Africa
    • 12.6.5 Rest of Middle East & Africa

13 Key Developments

  • 13.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 13.2 Acquisitions & Mergers
  • 13.3 New Product Launch
  • 13.4 Expansions
  • 13.5 Other Key Strategies

14 Company Profiling

  • 14.1 Chr. Hansen Holding A/S
  • 14.2 Lallemand Inc.
  • 14.3 Koninklijke DSM N.V.
  • 14.4 Novozymes A/S
  • 14.5 Microba Life Sciences
  • 14.6 Archer Daniels Midland Company (ADM)
  • 14.7 Kemin Industries Inc.
  • 14.8 DuPont de Nemours Inc.
  • 14.9 Cargill Incorporated
  • 14.10 Evonik Industries AG
  • 14.11 Alltech Inc.
  • 14.12 Calpis Limited
  • 14.13 Phibro Animal Health
  • 14.14 Biomin Holding GmbH
  • 14.15 Bayer AG
  • 14.16 Probi AB
  • 14.17 Novus International
  • 14.18 Sabinsa Corporation
  • 14.19 Kerry Group
  • 14.20 Unique Biotech Limited
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦